BCAX Bicara Therapeutics Inc.
Bicara Therapeutics Inc. (BCAX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $656.7K.
Where they traded
Last open-market purchase: February 26, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Cohlhepp Ryan 2 fills | President, COO & Interim CEO | Sell 10b5-1 | 17,500 | $22.90 | $400.7K | 185,083 −8.6% of holding | |
| Cohlhepp Ryan | President and COO | Sell 10b5-1 | 18,750 | $27.98 | $524.5K | 181,641 −9.4% of holding | |
| Hyep Ivan | Chief Financial Officer | Sell 10b5-1 | 12,500 | $27.97 | $349.6K | 129,855 −8.8% of holding | |
| Mazumdar Claire | Chief Executive Officer | Sell 10b5-1 | 10,000 | $27.98 | $279.8K | 362,152 −2.7% of holding | |
| Mazumdar Claire 2 fills | Chief Executive Officer | Sell 10b5-1 | 10,000 | $28.42 | $284.2K | 362,180 −2.7% of holding | |
| Cohlhepp Ryan | President and COO | Sell 10b5-1 | 536 | $29.00 | $15.5K | 181,641 −0.3% of holding | |
| Cohlhepp Ryan 3 fills | President and COO | Sell 10b5-1 | 28,214 | $28.98 | $817.6K | 187,558 −13.1% of holding | |
| Hyep Ivan 3 fills | Chief Financial Officer | Sell 10b5-1 | 28,000 | $28.85 | $807.7K | 135,098 −17.2% of holding | |
| Hyep Ivan | Chief Financial Officer | Sell 10b5-1 | 9,200 | $20.42 | $187.9K | 145,355 −6% of holding | |
| Mazumdar Claire 2 fills | Chief Executive Officer | Sell 10b5-1 | 15,000 | $20.04 | $300.6K | 365,130 −3.9% of holding | |
| Cohlhepp Ryan 2 fills | President and COO | Sell 10b5-1 | 12,500 | $20.29 | $253.6K | 196,141 −6% of holding | |
| Raben David | Chief Medical Officer | Sell 10b5-1 | 5,500 | $22.88 | $125.8K | 55,286 −9% of holding | |
| Hyep Ivan | Chief Financial Officer | Sell 10b5-1 | 9,200 | $23.00 | $211.6K | 145,355 −6% of holding | |
| Mazumdar Claire | Chief Executive Officer | Sell 10b5-1 | 15,000 | $23.61 | $354.1K | 362,152 −4% of holding | |
| Cohlhepp Ryan 2 fills | President and COO | Sell 10b5-1 | 12,500 | $23.01 | $287.6K | 200,641 −5.9% of holding | |
| Raben David | Chief Medical Officer | Sell 10b5-1 | 5,500 | $18.95 | $104.2K | 55,286 −9% of holding | |
| Hyep Ivan | Chief Financial Officer | Sell 10b5-1 | 9,200 | $18.52 | $170.3K | 145,355 −6% of holding | |
| Mazumdar Claire | Chief Executive Officer | Sell 10b5-1 | 1,596 | $18.95 | $30.2K | 339,392 −0.5% of holding | |
| Mazumdar Claire | Chief Executive Officer | Sell 10b5-1 | 6,905 | $18.78 | $129.7K | 339,392 −2% of holding | |
| Mazumdar Claire | Chief Executive Officer | Sell 10b5-1 | 6,499 | $18.84 | $122.4K | 339,392 −1.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.